166 related articles for article (PubMed ID: 25469886)
1. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.
McGraw KL; Basiorka AA; Johnson JO; Clark J; Caceres G; Padron E; Heaton R; Ozawa Y; Wei S; Sokol L; List AF
PLoS One; 2014; 9(12):e114249. PubMed ID: 25469886
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin receptor signaling is membrane raft dependent.
McGraw KL; Fuhler GM; Johnson JO; Clark JA; Caceres GC; Sokol L; List AF
PLoS One; 2012; 7(4):e34477. PubMed ID: 22509308
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.
Basiorka AA; McGraw KL; De Ceuninck L; Griner LN; Zhang L; Clark JA; Caceres G; Sokol L; Komrokji RS; Reuther GW; Wei S; Tavernier J; List AF
Cancer Res; 2016 Jun; 76(12):3531-40. PubMed ID: 27197154
[TBL] [Abstract][Full Text] [Related]
5. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM
Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948
[TBL] [Abstract][Full Text] [Related]
6. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
Ebert BL; Galili N; Tamayo P; Bosco J; Mak R; Pretz J; Tanguturi S; Ladd-Acosta C; Stone R; Golub TR; Raza A
PLoS Med; 2008 Feb; 5(2):e35. PubMed ID: 18271621
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
8. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide for treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
[TBL] [Abstract][Full Text] [Related]
11. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
[TBL] [Abstract][Full Text] [Related]
12. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.
Cluzeau T; McGraw KL; Irvine B; Masala E; Ades L; Basiorka AA; Maciejewski J; Auberger P; Wei S; Fenaux P; Santini V; List A
Haematologica; 2017 Dec; 102(12):2015-2020. PubMed ID: 28983059
[TBL] [Abstract][Full Text] [Related]
13. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
14. Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietin dependence and enhances erythroid colony-forming unit, erythroid burst-forming unit, and granulocyte/macrophage progenitor growth.
Pharr PN; Hankins D; Hofbauer A; Lodish HF; Longmore GD
Proc Natl Acad Sci U S A; 1993 Feb; 90(3):938-42. PubMed ID: 7679218
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes.
Mittelman M; Gardyn J; Carmel M; Malovani H; Barak Y; Nir U
Leuk Res; 1996 Jun; 20(6):459-66. PubMed ID: 8709617
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Komrokji RS; Lancet JE; Swern AS; Chen N; Paleveda J; Lush R; Saba HI; List AF
Blood; 2012 Oct; 120(17):3419-24. PubMed ID: 22936658
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
19. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin Receptor Signaling and Lipid Rafts.
McGraw K; List A
Vitam Horm; 2017; 105():79-100. PubMed ID: 28629526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
